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Aims: Prevalence of Type 2 diabetes mellitus among Sudanese population was found to be 3.4% and associated
with high rates of complications and obesity. Different adipocytokines are secreted from adipose tissues, among
them adiponectin, which was shown to have insulins ensitizing properties and anti-inflammatory, anti-atherogenic
effect. The aim of this study was to characterize type 2 diabetes in Sudanese diabetic subjects and controls in
respect to hormones influencing or influenced by glucose metabolism.
Methods: 104 type 2 diabetic patients (45 men and 59 women), and 75 matched control subjects (34 men and 41
women) were studied. Fasting serum samples were used to measure adiponectin, leptin, insulin, proinsulin, ghrelin
and glucose. Body mass index, insulin/proinsulin ratio and (HOMA) insulin resistance and beta cell function were
also calculated.
Results: Adiponectin serum concentrations were significantly lower in subjects with type 2 diabetes compared with
controls subjects (P = 0.002), comparison between males and females did not reach significant levels in both diabetic
(P = 0.06) or controls (P = 0.16) groups. In the diabetic group adiponectin correlated positively with serum glucose,
negatively with serum proinsulin and HOMA beta cell function (P = 0.03) respectively and serum ghrelin (P = 0.003),
but not with BMI, HOMA insulin resistance, insulin or leptin. In controls serum adiponectin correlated negatively with
BMI (P = 0.002) but not with other variables.
Conclusions: The findings of this study suggest that, adiponectin concentrations independent on BMI as a measure
of adiposity, were mostly linked to insulin sensitivity and not to insulin resistance in Sudanese type 2 diabetic
subjects, where race specific regulation mechanisms or different type 2 diabetes phenotype suggested being a
major contributory factor in clarification the findings of this study.
Keywords: Diabetes mellitus, Sudan, Adiponectin, Ghrelin, LeptinIntroduction
Impaired insulin secretion or/and abnormal insulin action
and obesity are major characteristics for type 2 diabetes
mellitus [1-3]. The prevalence of diabetes mellitus in the
Sudanese population was 3.4% and type 2 diabetes mellitus
account for 75% of all diagnosed cases, among whom the
majority also has a family history of diabetes [4] and 40%* Correspondence: moawia.abdelgadir@medsci.uu.se
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distribution, and reproduction in any mediumof them are obese [5] In a population based study 40% of
the patients are found to be obese [5].
Adipose tissue was found to produce a variety of
adipocytokines including leptin, adipsin and tumor necro-
sis factor [6-11]. Adiponectin is the recently identified
most abundant among of them – is a 30. kDa protein
[12-14]. Mechanisms of regulation of adiponectin pro-
posed to be multifactorial. Involvements of genetic factors,
glucocorticosteroids, body fat distribution and insulin have
been shown in different studies [12,15,16]. Adiponectin
serum levels were found to be lower in type 2 diabetestral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Demographic and clinical characteristics of the
subjects
Characteristics Type 2 diabetes Controls
No. of subjects 104 75
Males/Females 45/59 34/41
Age (yrs) 53.8 ±10.7 53.4 ±8.9 (P = 0.83)
BMI (kg/m2) 23.5 ± 5.3 24.0 ±3.7 (P = 0.59)
Diabetes duration (yrs) 9.9 ± 7.9 -
Systolic BP (mmHg) 117 ±14 119 ±16.0 (P = 0.22)
Diastolic BP (mmHg) 79 ± 8 80 ± 10 (P = 0.71)
Adiponectin (μg/ml) 7.54 ± 4.62 9.56 ± 5.92 (P = 0.0017)
Gherlin (μg/ml) 26.78 ± 18.91 26.64 ± 8.78 (P = 0.99)
Leptin (ng/mL) 9.6 ± 7.9 14.9 ± 11.6 (P = 0.0066)
Glucose (mmol/L) 8.6 ± 4.4 4.2 ± 0.9 (P = 0.0001)
Insulin (pmol/L) 75 ± 47.0 67.6 ± 23.2 (P = 0.99)
Proinsulin (pmol/L) 26.3 ± 21.7 17.8 ± 12.8 (P = 0.0031)
PI/insulin ratio 0.38 ± 0.30 0.24. ± 0.12 (P = 0.0003)
HOMA IR 6.15 ± 0.92 5.58 ± 0.40 (P = 0.0001)
HOMA B 2.82 ± 1.26 4.62 ± 0.90 (P = 0.0001)
Mean ± SD Abbreviations: BP, blood pressure; PI, proinsulin.
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correlated with insulin resistance and measures of body
fat [20-23]. Besides its insulin.sensitizing properties
[23-25], adiponectin was also suggested to have an anti-
inflammatory, anti-atherogenic effect [26-28].
It is of interest to explore the association of adiponectin
with metabolic parameters in different populations where
ethnic diffrences were reported in som studies [29-34]. The
aim of this study was to characterize type 2 diabetes in
Sudanese diabetic subjects and controls in respect to hor-
mones influencing or influenced by glucose metabolism.
Research design and methods
One hundred and four diabetic patients (males/females,
45/59) were recruited from the outpatient diabetes clinic
at Omdurman Teaching Hospital, Khartoum, Sudan.
Inclusion criteria were treatment with diet and/or oral
hypoglycemic agents, age > 20 years and duration of
diabetes >1 year. They were treated with glibenclamide
(n = 80), glicalazide (n = 1), metformin (n = 4) and or
diet alone (n = 19). A BMI and age matched group of
75 (males/females, 41/34) apparently healthy non dia-
betic subjects, who live in the same area, were selected
as controls. Informed consent was obtained from all
subjects. The and ethical clearance was taken from com-
mittee at The Federal Ministry of Health approved of the
study. A questionnaire including personal details and clin-
ical characteristics was completed for all subjects. Blood
pressure, weight and height in light clothing without shoes
were measured and body mass index (BMI) was calculated.
In the fasting state blood samples were drawn for the de-
termination of serum adiponectin, leptin, ghrelin, glucose,
insulin and proinsulin. The samples were centrifuged
within 2 hours after collection and kept frozen at −20°C
until analyzed at the Department of Medicine, Malmö
University Hospital and Uppsala University Hospital,
Sweden. The demographic and clinical characteristics of
the subjects are shown in Table 1.
Adiponectin was analyzed using Human Adiponectin
RIA kit (Linco Research, St. Charles, MO, USA) of assay
specificity <0.01%, ghrelin was measured using Human
Ghrelin RIA kit (Linco Research, St. Charles, MO, USA)
of 100% specificity and leptin was measured using RIA kit
(Linco Research, St. Charles, MO, USA), detecting immu-
noreactive human leptin with sensitivity 0,5 ng/mL. Insu-
lin was measured with specific RIA cross reacting with
less than 0.2% proinsulin (Linko Research, St. Charles,
MO, USA). Total serum proinsulin levels were measured
using a goat antibody raised against human proinsulin,
human proinsulin standards and 125I-human proinsulin
as tracer (Linco Res. Inc.). This assay detects intact pro-
insulin (100%) and des.31,32 proinsulin (95%) but does
not crossreact with insulin, C-peptide or des-64,65 pro-
insulin (<0.1%). Serum glucose was analyzed using theglucose oxidase technique. Homeostasis model assess-
ment (HOMA) was used to assess pancreatic cell func-
tion (HOMA B) and insulin resistance (HOMA IR)
using fasting insulin and glucose concentrations by the
formula: HOMA-B (%) =20 X [insulin]/(glucose.3,5)
and HOMA-IR = insulin/(22,5e.ln[glucose]) [35].
Statistical analysis
All data were expressed as mean + SD. Statistical analysis
was performed using the program SAS for Windows 6.12
(SAS Institute, Cary NC). T-test was used for comparison
between groups for variables with normal or log normal
distribution. Pearson’s correlation coefficient was used to
determine association with variables normal or log normal
distribution. Adjustment calculated as Pearson’s partial
correlation coefficients.
Results
Table 1 shows the characteristics of the two study groups.
Fasting adiponectin serum levels were significantly lower
in diabetic subjects compared to controls (Table 1). How-
ever, differences did not reach significance when males
and females in both diabetic 6.9 ± 3.5 vs. 8.4 ± 5.2 μg/ml,
(P = 0.06) and control 9.1 ± 6.3 vs. 10.2 ± 5.4 μg/ml,
(P = 0.16) groups where compared. Adiponectin did not
correlate to BMI in diabetic group(r = −0.12, P = 0.24), but
it correlated significantly negative in the control subjects
(r = −0.38, P = 0.002).
Adiponectin concentrations correlated significantly
negative with HOMA B in subjects with type 2 diabetes
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ation to HOMA IR was found in subjects with type 2 dia-
betes (r = 0.08, P = 0.44) or controls (r = −0.16, P = 0.33).
Serum adiponectin in diabetic subjects did not correlate
significantly with systolic (r = −0.13, P = 0.20) and diastolic
(r = −0.13, P = 0.20) blood pressure, this correlation
remained non-significant after adjustment for BMI. In
non-diabetic subjects, the systolic and diastolic blood
pressures were not related to adiponectin concentrations.
Adiponectin levels correlated significantly negative to
serum proinsulin in diabetic subjects (r = −0.22, P = 0.03),
but not to insulin (r = −0.16, P = 0.12) or proinsulin/insulin
ratio (r = −0.18, P = 0.06), whereas no correlation was seen
between adiponectin and the insulin or proinsulin/insulin
ratio in control subjects (r = 0.03, P = 0.83) and (r = −0.01,
P = 0.53).
Also serum adiponectin levels correlated significantly
positive with serum glucose in diabetic subjects (r = 0.22,
P = 0.03), however no significance was found between
adiponectin and serum glucose in control subjects
(r = −0.1, P = 0.5).
Type 2 diabetic subjects treated by sulphonylurea, had
almost the same levels of adiponectin (7.3 ± 4.6 μg/ml,
n = 81) compared to those treated with diet alone, or
metformin (7.6 ± 4.7 μg/ml, n = 23, P = 0.99). Adjusting
for BMI (P = 0.87) did not changed the results. The
subjects treated with sulphonylurea had, however, also
lower BMI than the other group, (22.7 ± 4.9 versus
26.1 ± 5.9, P = 0.0017), but no differences in HOMA B
(P = 0.28) or HOMA IR (P = 0.15) was found. Fasting
serum leptin levels did not correlate with adiponectin
levels neither in diabetic (r = 0.03, P = 0.73) nor in con-
trol (r = −0.01, P = 0.1) groups.
However, serum adiponectin level correlated signifi-
cantly with serum ghrelin in diabetic subjects (r = 0.29,
P = 0.003), but not in control subjects (r = 0.18, P = 0.14).
Discussion
In agreement with previous reports adiponectin was
found to be significantly lower in subjects with diabetes
compared to controls [17-19]. However, in contrast with
the studies that have shown that irrespective of ethnicity,
adiponectin concentrations negatively correlated to
BMI and insulin resistance in subjects with diabetes
[14,17,18,23]. Our findings showed that adiponectin in
diabetic subjects correlated positively with fasting glu-
cose and negatively with fasting serum proinsulin and
HOMA cell function but not with the insulin or HOMA
insulin resistance or even BMI. In the control subjects
adiponectin correlated negatively only with BMI. The
difference in adiponectin concentrations and its associ-
ation in both groups could be explained by the fact that
adiponectin ameliorates insulin sensitivity, where healthy
controls have significantly increased adiponectin levels,thus have significantly lower insulin resistance and bet-
ter cell function (Table 1), and that goes in agreement
with some studies [36]. However, the finding in this
study that showed similar adiponectin levels in two dia-
betic subgroups (according to type of treatment) that
have significantly different BMI, and have no differences
in HOMA IR or HOMA B, could confirm the finding
that adiponectin concentrations are linked also to insulin
sensitivity [24,25] irrespective to measures of adiposity
[36]. Relaying on the findings that adiponectin related to
proinsulin and HOMA cell function in diabetic subjects,
it would be useful to find whether there is a possible role
of adiponectin in mediation hepatic IR and decreased
cell function in type 2 diabetes, as has been recently
demonstrated that the interaction between muscle and
hepatic receptors through activation of AMP kinase
could mediate adiponectin effects [37].
Besides, due to differences in fat distribution, as dia-
betics have less subcutaneous fat and increased visceral
fat, lipotoxic effects could lead also to deterioration of
pancreatic cell function and increased hepatic and per-
ipheral insulin resistance in type 2 diabetes [38].
In both groups we did not observe significant gender
differences in adiponectin concentrations [39]. Also no as-
sociation was found between adiponectin and leptin and
that is similar to a previous report [40]. Data on associ-
ation between adiponectin and ghrelin in diabetes is
scarce, and no correlation has been found in non diabetic
subjects [41,42]. Serum adiponectin and ghrelin concen-
trations were found to be significantly correlated only in
subjects with diabetes in this study, where ghrelin corre-
lated significantly negative with fasting glucose in both
diabetic (r = 0.21, P = 0.03) and control subjects (r = 0.40,
P = 0.008). The link between adiponectin and ghrelin in
diabetic subjects could be through the hepatic glucose
homeostasis, which is enhanced by ghrelin and suppressed
by adiponectin [43]. Despite the generally known associ-
ation between adiponectin and some metabolic and adi-
posity characteristics, the absence of this relationship as
shown in this study, could support the hypothesis that
adiponectin concentration could be regulated differently
in different populations, particularly in populations with
an African origin [29-34].
In conclusion, we showed in this study different associ-
ation of adiponectin in Sudanese diabetic and healthy sub-
jects, contrasting to other reports of different populations.
Adiponectin concentrations are mostly linked to insu-
lin sensitivity independent on BMI as a measure of adi-
posity and not to insulin resistance in type 2 diabetic
Sudanese subjects. Also adiponectin concentrations
were linked to ghrelin levels in subjects with type 2 dia-
betes. However, race specific regulation mechanisms or
a different type 2 diabetes phenotype could be factors
in clarification the findings of this study. Further
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oriented approach to elucidate the mechanisms under-
lying these perturbations of adiponectin concentrations
are required.
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